SCLX Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—Forward 2.66
EPS (TTM)$-40.500.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$48.8MMicro cap
Valuation
- Forward P/E
- 2.66
- PEG ratio
- —
- P/B
- 28.85
- P/S (TTM)
- 1.44
- EV/EBITDA
- -2.64
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- -373.5%
- Revenue growth YoY
- 72.1%
- Dividend yield
- —
- Beta
- 1.71
Last earnings
Apr 10, 2026 · Estimate $-0.47 · Reported $-1.17
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Scilex Holding Company
Company profileScilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company is headquartered in Palo Alto, California.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 960 SAN ANTONIO ROAD, PALO ALTO, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$48.8M
Shares outstanding$7.0M
52W high$21.34
52W low$2.62
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent